Latest News

21 October 2014

Starpharma Boardroom Radio Interview

Starpharma is pleased to provide investors with the opportunity to listen to an audio interview with Chief Executive Officer Dr Jackie Fairley on Boardroom Radio (BRR).

Read more

20 October 2014

Extension of Share Purchase Plan

Starpharma advises that it has extended the closing date of its share purchase plan (SPP) following the release today of preliminary positive DEP™ docetaxel pharmacokinetic (PK) findings from its Phase I clinical trial. 

Read more

20 October 2014

DEP™ docetaxel shows intended longer duration and increased exposure

Starpharma today announced it has completed preliminary analyses of the pharmacokinetics (PK) of DEP™ docetaxel from the ongoing Phase 1 human clinical trial using results from the first cycle of dosing for several patients.  

Read more

14 October 2014

Starpharma to present at US Drug Delivery Conference

Starpharma today announced that it will be presenting its DEP™ platform at the 4th Annual Partnership Opportunities in Drug Delivery (PODD) conference in Boston this week.

Read more

In the media

7 August 2014

The Business on ABC TV: Interview with Starpharma CEO Jackie Fairley

Starpharma CEO Jackie Fairley joins The Business’ Presenter Ticky Fullerton to discuss TGA approval of a VivaGel coated condom in depth, revisiting the shorting issue covered prior on the show, the benefits of the announcement to broader Australian innovation, and a business update on Starpharma’s DEP docetaxel drug development. 

Read more

7 August 2014

Glamour UK: Potential Huge News: This New Condom May Be Able to Kill HIV, Herpes, and Other STDs

Glamour UK, a magazine for women with a UK online readership of 3.38 million, covered the announcement that Starpharma had received TGA approval for VivaGel coated condoms. 

Read more

7 August 2014

The Washington Times: HIV-killing condom to soon hit shelves in Australia

The Washington Times’ picked up the announcement that Starpharma and Ansell have received TGA approval of the VivaGel coated condom from The Daily Mail UK.  

Read more

7 August 2014

The Daily Mail: First condom designed to kill HIV "could be available to buy within months"

In an article that goes into a significant amount of scientific detail for a mainstream news publication, the Daily Mail covered the TGA of VivaGel coated condoms announcement. 

Read more

Shareholder Updates

7 October 2014

Shareholder Update October 2014

In this Issue:

› Encouraging clinical data for DEP™ docetaxel

› VivaGel® condom approved for sale in Australia – Launch imminent

› VivaGel® for BV: SPA agreement for Phase 3 and commercialisation activities for Symptomatic Relief

› Starpharma completes $18M Placement; launches $5M SPP

› Dendrimer-enhanced agrochemicals

› Full Year 2014 annual financial results


Download: Shareholder Update October 2014 (pdf file, 1MB)

12 June 2014

Shareholder Update: June 2014

In this issue:

› VivaGel® BV prevention of recurrence: start of phase 3 trials close

› R&D tax incentive cash received

› DEP™ docetaxel trial progressing well

› VivaGel®-coated condom: preparing for launch

› VivaGel® BV symptomatic relief product: commercial and regulatory progress

› Strong results for dendrimer enhanced agrochemicals


Download: Shareholder Update: June 2014 ( pdf file, 2MB)

Sign up to receive news here

© Starpharma Holdings Limited 2014